Cefuroxime Dosing in Hypoalbuminemia

Understanding the Pharmacokinetic Impact

Cefuroxime exhibits moderate protein binding (approximately 33-50% under normal conditions), which is significantly less than highly protein-bound beta-lactams like ceftriaxone (85-95%) or ertapenem (85-95%) 1, 2
When albumin decreases, the unbound (free) fraction of cefuroxime increases, leading to enhanced tissue penetration and increased renal/hepatic clearance 1, 2
The free fraction is the pharmacologically active component that diffuses across biological membranes and achieves antibacterial effect 1

The French Society of Pharmacology and Therapeutics recommends using standard cefuroxime dosing without adjustment in patients with albumin ≥25 g/L 1, 2
For severe infections in patients with albumin ≥25 g/L, the recommended dose is 1.5 g IV every 8 hours 3
For surgical prophylaxis in patients with albumin ≥25 g/L, the recommended dose is 1.5 g IV single dose 30-60 minutes pre-incision 4
In critically ill patients with albumin <20 g/L, consider measuring albumin at treatment initiation to guide prescription and implement therapeutic drug monitoring (TDM) if available, targeting unbound concentrations 1, 2

The French Society of Pharmacology and Therapeutics recommends measuring albumin (or total plasma proteins) at treatment onset in critically ill patients and performing TDM 24-48 hours after treatment initiation 1, 2, 5
Target unbound cefuroxime concentrations >4× MIC (typically >32 mg/L for resistant organisms) 1

The French Society of Anaesthesia and Intensive Care Medicine advises against using estimated GFR formulas (MDRD, CKD-EPI, Cockcroft-Gault) in critically ill patients, as they are inaccurate in acute illness 1, 2
Residual renal function in patients on renal replacement therapy significantly contributes to cefuroxime clearance 5
Ceftriaxone is particularly problematic in hypoalbuminemia due to 85-95% protein binding and documented difficulty penetrating low-protein ascitic fluid 6